Core Viewpoint - On November 21, Aotai Bio experienced a decline of 2.99% with a trading volume of 24.0661 million yuan, indicating a potential shift in investor sentiment and market dynamics [1]. Financing Summary - On November 21, Aotai Bio had a financing buy-in amount of 3.1237 million yuan and a financing repayment of 2.8837 million yuan, resulting in a net financing buy of 240,000 yuan [1]. - As of November 21, the total financing and securities lending balance for Aotai Bio was 86.7704 million yuan, which accounts for 1.68% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. - The financing balance of 86.7704 million yuan exceeds the 70th percentile level over the past year, suggesting a relatively high position in terms of financing [1]. Shareholder and Financial Performance Summary - As of October 31, Aotai Bio had 5,665 shareholders, a decrease of 1.29% from the previous period, while the average circulating shares per person increased by 1.31% to 13,994 shares [2]. - For the period from January to September 2025, Aotai Bio reported a revenue of 633 million yuan, reflecting a year-on-year growth of 2.44%, while the net profit attributable to shareholders decreased by 3.91% to 190 million yuan [2]. Dividend and Institutional Holdings Summary - Aotai Bio has distributed a total of 1.28 billion yuan in dividends since its A-share listing, with 955.6 million yuan distributed over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 2.1873 million shares, a decrease of 387,400 shares from the previous period, while Guotai Junan Value Advantage Flexible Allocation Mixed A (000362) entered the top ten as the ninth largest shareholder with 713,300 shares [3].